{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:10Z","timestamp":1790695990508,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00832","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T01:13:18Z","timestamp":1568077998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Part I of GANNET53: A European Multicenter Phase I\/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer\u2014A Study of the GANNET53 Consortium"],"prefix":"10.3389","volume":"9","author":[{"given":"Isabelle","family":"Ray-Coquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Alexandre","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute Martha","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Leunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain Gustave","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.ejca.2015.07.022","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999\u20132007: results of the EUROCARE-5 study","volume":"51","author":"Sant","year":"2015","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cdd.2013.17","article-title":"Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis","volume":"20","author":"Hanel","year":"2013","journal-title":"Cell Death Differ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","article-title":"Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells","volume":"9","author":"Li","year":"2011","journal-title":"Mol Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature14430","article-title":"Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment","volume":"523","author":"Alexandrova","year":"2015"},{"key":"B17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ccell.2018.07.004","article-title":"Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion","volume":"34","author":"Schulz-Heddergott","year":"2018","journal-title":"Cancer Cell."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2683","DOI":"10.1038\/cddis.2017.108","article-title":"Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner","volume":"8","author":"Alexandrova","year":"2017","journal-title":"Cell Death Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/annonc\/mdv220","article-title":"A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)","volume":"26","author":"Ramalingam","year":"2015","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-14-0979","article-title":"First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas","volume":"17","author":"Rajan","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human Phase I dose-escalation study of the HSP90 Inhibitor AUY922 in patients with advanced solid tumors","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.taap.2013.09.018","article-title":"Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors","volume":"273","author":"Zhou","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/tx050237e","article-title":"Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications","volume":"19","author":"Cysyk","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s10637-011-9790-6","article-title":"Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models","volume":"30","author":"Proia","year":"2012","journal-title":"Invest New Drugs."},{"key":"B29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","article-title":"Weekly paclitaxel in the treatment of recurrent ovarian cancer","volume":"7","author":"Baird","year":"2010","journal-title":"Nat Rev Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T17:32:42Z","timestamp":1569346362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":29,"alternative-id":["10.3389\/fonc.2019.00832"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00832","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"article-number":"832"}}